Skip Navigation LinksHome > Professional Development > eLearning > Update on the Role of Antifibrinolytics in Patient Blood Management

Update on the Role of Antifibrinolytics in Patient Blood Management

Please note: AABB reserves the right to make updates to this program.    
                      
Live Program: Thursday, November 9, 2017 - On-Demand Available

Master Program Number: 17EL-169 (see program format numbers below under Registration)

Educational Track: Technical/Clinical Track
Topic:  Patient Blood Management
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors, Perfusionists, Medical Directors, Residents, Hospital Blood Banks
Teaching Level: Basic-Advanced

Director/Moderator: Kathy Puca, MD, Medical Director, Blood Center of Wisconsin, Part of Versiti, Milwaukee, WI
Speaker: Jerrold Levy, MD, FAHA, FCCM, Professor of Anesthesiology, Associate Professor of Surgery Co-Director, Cardiothoracic ICU, Duke University Hospital, Chapel Hill, NC

Learning Objectives

After participating in this educational activity, participants should be able to:

  • Describe the currently available antifibrinolytics and their role in hemostasis and reducing surgical blood loss.
  • Review the growing use of antifibrinolytics in various non-trauma surgical populations.
  • Discuss the impact perioperative use of antifibrinolytics has on reducing blood transfusions.

Program Description

Antifibrinolytic therapy has been used for years in cardiac surgery and liver transplantation where the risk of bleeding is high. More recently, its role as a blood conservation strategy has become common practice in joint replacement procedures, resulting in a dramatic decline in blood transfusion requirements in these surgical patients.  Likewise, reports of the use of antifibrinoltyics in complex spine surgery and other neurosurgical procedures has reduced bleeding and the need for transfusions. This program will describe the expanding use of antifibrinolytics in non-trauma surgical populations and review its effectiveness as a patient blood management strategy. 

Registration

   Program #
Single Viewer: On-Demand Register17EL-4031-169
Group Viewing: On-Demand Register17EL-8031-169

Speaker Biographies

Dr. Jerrold Levy is Professor of Anesthesiology, Associate Professor of Surgery, and Co-Director of the Cardiothoracic Surgical Intensive Care Unit at Duke University Medical Center in Durham, NC. He obtained his medical degree from the University of Miami, FL, where he was an intern in medicine, and undertook his residency in the Department of Anesthesiology of the Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, where he also completed fellowships in both Respiratory ICU and Cardiac Anesthesiology.  He previously was Professor, Deputy Chair for Research, and Chief of Cardiothoracic Anesthesiology at Emory University. His clinical and research interests include therapeutic strategies to prevent and treat bleeding; anticoagulation and its reversal, clinical applications of recombinant and purified protein concentrates, therapeutic approaches to shock, and anaphylaxis. Some of his appointments include Executive Editor of Anesthesiology, consultant to the FDA‘s Blood Products Advisory Committee, member of the AHA Leadership Council on Cardiovascular Surgery, and Co-chair of the Subcommittee on Perioperative Hemostasis for the International Society of Thrombosis and Hemostasis.  He has authored over 400 publications, including original research articles, reviews, books, and book chapters.   ​